Apogee doses first patient in Part B of Phase 2 APEX trial for APG777 in atopic dermatitis

Apogee Therapeutics, Inc.

Part A enrolled 123 patients (exceeded ~110 target) randomized 2:1 APG777 vs placebo; >90% power for primary endpoint.
Part A 16-week induction data expected mid-2025; maintenance data first half 2026; Part B 16-week data second half 2026.
APG777 modeled to exceed lebrikizumab exposures by ~30–40% with ~70–90% fewer maintenance injections vs current therapies.
Plans to initiate Phase 1b combo study of APG777 and APG990 (anti-OX40L) in AD in 2025 with readout in second half 2026.
Expansion plans include Phase 1b/2b asthma trials in 2025 and Phase 2 EoE trial in 2026.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.